配对盒基因 8（PAX8）在高级别、晚期（Ⅲ期和Ⅳ期）卵巢浆液性癌中的表达。
Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma.
机构信息
Department of Pathology, University of Southern California, Los Angeles, CA 90033-5000, USA.
出版信息
Gynecol Oncol. 2012 Oct;127(1):198-201. doi: 10.1016/j.ygyno.2012.06.012. Epub 2012 Jun 15.
OBJECTIVES
Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC.
METHODS
PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS).
RESULTS
We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome.
CONCLUSION
Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.
目的
配对盒基因 8（PAX8）是一种转录因子，在卵巢浆液性癌（OSC）中过度表达。使用 shRNA 沉默 PAX8 导致卵巢癌细胞系的细胞活力下降，表明其可用作靶向治疗剂。PAX8 在 OSC 中的预后价值仍知之甚少。本研究旨在评估 PAX8 作为晚期 OSC 患者的预后生物标志物。
方法
使用组织微阵列对 148 例 OSC 进行免疫组织化学评估，并将表达与以下临床病理变量相关联；诊断时的年龄、肿瘤分期、最佳减瘤术、无复发生存（RFS）和总生存（OS）。
结果
我们发现 PAX8 在 61%的病例中表达。PAX8 与肿瘤分期、最佳减瘤术和疾病复发均无关联。此外，PAX8 未能对疾病结局具有预测价值。
结论
尽管表明 PAX8 蛋白不是高级别、晚期 OSC 患者的有用预测标志物，但在大量此类病例中 PAX8 的过度表达使得抑制 PAX8 成为一种非常有吸引力的靶向治疗方法。
Zotero 插件